Where does Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd ranks #42,947 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

Is Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd.

What does claim depth mean for Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's patents?

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's patents average 17.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd

Q: How many patents does Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd hold?

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd holds 6 US utility patents granted between 2020 and 2022, spanning 5 technology areas.

Q: What is Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's Innovation Score?

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd has an Innovation Score of 26.2 out of 100 (19th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Q: What technology areas does Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd focus on?

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's top technology area is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media) with 6 patents, ranking #1,557 of 4,144 assignees active in that subclass. Grants appear in 5 CPC subclasses total.

Q: How is the Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO PatentsView assignee record - 6 granted patents across 5 technology areas, recorded in grant years 2020–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Shanghai ranks #42,947 of 49,997 tracked US assignees by granted-patent volume, with 6 patents across 5 technology areas.

#42,947
of 49,997 US assignees by volume: 19th percentile
by Innovation Score (26.2/100): 17.0
avg claims per patent

USPTO PatentsView assignee plate

Corpus R42947 · Foreign Corporation #42,947 · 6 grants

GRANTS-MICRO · LOWER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 6 grants
LOWER-Q #42,947/49,997
PHOTO-FINISH Shanghai Microport…
CPC-NARROW C12N · 5 areas
INNOV-THIN 26.2/100
CLAIMS-RICH 17.0 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2020–2022 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: Shanghai Microport EP Medtech Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Shanghai’s 26.2 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 6.7 pts (26%) Velocity 1.3 pts (5%) Breadth 7.9 pts (30%) Claim depth 10.2 pts (39%)

Qualcomm Incorporated · highest

85
Shanghai Unicar-ther… · this assignee

26
3D Lighting… · lowest

7

What this shows Shanghai's Innovation Score is 26.2/100 (19th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Shanghai?

Each dot is one of Shanghai’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Shanghai’s own 17.0 claims/patent is ABOVE the 9.7 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Shanghai vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Shanghai's grants concentrate

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media). Peak complete grant year is 2021 (3 grants) versus a trough of 1 in 2022. By volume, Shanghai sits between Shanghai Microport EP Medtech Co., Ltd. and Shei Chung Hsin IND. Co., Ltd..

Shanghai's three-year grant acceleration

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd shows 1 grants in 2022–2024 against only 5 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Shanghai Micropor…

6
Shanghai NEW Toba…

6
Shanghai Runhood…

6
Shanghai Tianyang…

6
Shanghai United I…

6
Shanghai Vision M…

6
Shantou Chenghai…

6
Shei Chung Hsin I…

6
Shanghai Unicar-t… ◀

6

What this shows Shanghai holds 6 patents at rank #42,824, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Shanghai

By rank, the assignees closest to #42,824 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Shanghai's primary technology class.

Shanghai's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

26 19th percentile higher than 19% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2020–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.

View data table

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2020	2	33.3%
2021	3	50.0%
2022	1	16.7%

Which technologies does Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd patent most?

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C07K - Peptides 5

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 5

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 1

Top 5 of 5 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's patent record in context - here's where to go next.

Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd's lead technology class is C12N (Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media), 100% of its portfolio - see every assignee active in that class. Explore C12N
Ranked #42,947 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Shanghai Unicar-therapy Bio-medicine Technology Co., Ltd against Shanghai Microport EP Medtech Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 26.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.